At BioNet, our Research and Development (R&D) efforts are at the forefront of vaccine innovation, combining cutting-edge science with a mission to address urgent public health challenges. Our R&D focuses on creating next-generation vaccines using advanced platforms, including recombinant, DNA, and mRNA technologies.
Revolutionizing vaccine platforms
Recombinant vaccines have been shown safe and effective. BioNet used recombinant technology to produce a pertussis vaccine containing a genetically-inactivated pertussis toxin.
Leveraging its expertise in recombinant DNA technology, BioNet also developed DNA vaccines against SARS-CoV-2.
BioNet has been developing genetically-designed vaccines using its proprietary “plug-and-play” design and production process enabling the rapid GMP production of mRNA vaccines.
Patents for our technology have been granted in many countries including the USA. We have been collaborating with partners to expand our pipeline of recombinant vaccines.
Our clinically-proven mRNA plug-and-play platform enables the rapid development of a wide range of vaccines candidates. We have been collaborating with vaccine developers including academic partners to produce mRNA vaccines in our GMP facilities to advance local and global projects from research up to clinical trial stages.